Full-Year 2026 Outlook
We are providing the following outlook for the full year ending December 31, 2026. This outlook excludes the impact of any future practice affiliations or acquisitions that have not yet closed. As a result, actual results may differ materially depending on the timing and number of future affiliations or acquisitions completed during the year.
| Year Ending | Year Ended | Percent | |
| December 31, 2026 | December 31, 2025 | Change | |
| ($ in millions) | (Outlook) | (Actual) | (At Midpoint) |
| Revenue | $254.0 – $258.0 | $244.5 | 4.7% |
| Adjusted EBITDA | $21.0 – $23.0 | $22.0 | - |
| Adjusted EBITDA margin | 8.3% - 8.9% | 9.0% |
Our outlook includes 3.5% to 5.0% same practice revenue growth and approximately $2 million recurring public company costs we expect to incur in 2026. The outlook assumes continued patient demand across general and specialty services, stable reimbursement trends across commercial and government payors, ongoing recruitment and retention initiatives, and contributions from recently acquired and affiliated practices and de novos.
Contact Us
Contact Number :+852 3852 8500
English